With responses to current treatments varying among patients with spinal muscular atrophy (SMA), the researchers emphasized the importance of more prognostic markers for improved decision making.
A lysosomal aspartyl protease highly expressed in the central nervous system and in skeletal and cardiac muscle may serve as a potential new biomarker in spinal muscular atrophy (SMA), found a group of researchers.
The group, validating cathepsin D in samples of cerebral spinal fluid (CSF) from patients with SMA, found that the protein may be an indicator of treatment response. With responses to current treatments varying among patients with SMA, the researchers emphasized the importance of more prognostic markers to better assist with decision making in the rare disease.
The 29 samples included in the study were collected from patients receiving nusinersen. Analyses of the samples showed that there were significant drops in cathepsin D levels among all patients who were aged at least 2 months at the beginning of treatment. Compared with the significant decrease seen in older patients, levels of cathepsin D increased in patients who were aged under 2 months.
“No physiological inhibitor of Cathepsin D exists in eukaryotic cells, hence the observed decline in patients ≥2 months of age is more likely to be secondary to changes in neuronal protein hemostasis than to yet unidentified other regulatory mechanisms,” explained the researchers. “We hypothesize, that Cathepsin D serves as a biomarker of neurodegeneration and disease activity, which decreases slowly in natural history.”
The researchers observedthat over the 300 days of treatment, declines were only significant among the group of 14 patients who responded to treatment. There was a trend, albeit less pronounced, among patients who did not respond to treatment. Baseline levels of cathepsin D also had implications for treatment response. Baseline values of the protein were lower among patients who responded to treatment than among those who did not response.
Among patients who were aged 6 years or older, the decrease in cathepsin D levels persisted (paired t-test: day 1 vs. day 63, P = .016).
“Although our cohort was too small to compare age-groups and SMA subtypes within the group of ‘treatment responders’, we believe these results to be very promising as they indicate suitability of Cathepsin D levels to serve as biomarker in SMA also in older patients – in combination with analysis of pNF-L in adolescents or alone in adult patients,” commented the researchers. “However, further validation studies in larger cohorts and in easier to obtain biomaterials like serum samples will be needed to validate the applicability across different treatment regimens.”
The researchers also found that cathepsin D is downregulated in human SMA muscle, based on 7 muscle biopsies from treatment-naïve patients.
The potential of cathepsin D as a biomarker was originally revealed by the researchers during an untargeted proteomic analysis of samples of CSF from 3 patients with SMA type 1. Profiling of the samples was performed on days 1, 14, and 180 of nusinersen treatment. In addition to cathepsin D, upregulated Cyclophilin A was identified as a possible link to amyloid-associated pathophysiology.
Reference
Schorling D, KölbelH, Hentschel A, et al. Cathespin D as biomarker in CSF of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol. Published online March 23, 2022. doi: 10.1111/ene.15331
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen